A Win for Science, with Profound Implications for Industry: FDA Rejects MDMA
Mad in America
AUGUST 14, 2024
By late 2023, the general public perception was of two strong phase 3 trials that demonstrated the treatment’s efficacy in healing those with PTSD. Perhaps because MDMA-assisted therapy isn’t a simple drug to be prescribed by psychiatrists. Could their pressure—pharma giants’ influence on the FDA —have led to this decision?
133 
Let's personalize your content